Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, September 16 at 2:00 PM EDT

Register Free →

Clinical Trial Management & Coordination

Active
Grant

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

This subcontract for Clinical Trial Management and Coordination supports the Department of Defense and the Defense Health Agency Contracting Activity in executing melanoma research projects. The selected provider will perform operational execution for prime contractors, focusing on prospective enrollment, study architecture implementation, variable management, and the execution of blinding and randomization procedures to ensure unbiased results. The role requires specialized expertise in clinical trial methodology and IRB compliance to deliver comprehensive study execution reports and completed data sets. This opportunity was posted on May 21, 2026, with a response deadline of October 14, 2026, falling under NAICS code 622310.

General Info

Subcontract for DoD melanoma research clinical trial management, coordination, and operational execution.

Agency

Department Of Defense → Defense Health Agency Contracting Activity - DhacaView Agency

NAICS

622310 - Specialty (except Psychiatric and Substance Abuse) HospitalsView NAICS

Place of Performance

Not specified

Set-Aside

NONE

Documents

This scope was carved out of HT942526MRPSRA.

The full solicitation package (1 document), including the RFP, is on the prime solicitation, not on this scope.

View the prime solicitation

DoW Melanoma Research Program Survivorship Research Award

AI Contract Breakdown

Uniform Contract Format

No contract breakdown available.

Cannot generate Contract Breakdown because no documents were found from this contract's source.

Timeline

Posted

subcontract

Response Deadline

Submission deadline

Response Deadline

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment Of Defense → Defense Health Agency Contracting Activity - Dhaca
ContactsNo contacts available
OfficeN/A
Organization / Agency
Department Of Defense → Defense Health Agency Contracting Activity - Dhaca
View Agency Profile
Office AddressN/A
ContactsNo contact information available

Full Description

Show more
Performs operational execution of clinical trials for prime contractors on U.S. Department of War melanoma research projects. Manages prospective enrollment, implements study architecture, manages study variables, and executes blinding and randomization procedures to minimize bias. Requires expertise in clinical trial methodology and IRB compliance. Delivers completed clinical trial data sets and study execution reports.

Similar Contracts

Same NAICS industry code

More opportunities from Department Of Defense → Defense Health Agency Contracting Activity - Dhaca

Same awarding agency

NAICS: 541715
Grant
DoW Breast Cancer, Breakthrough Award Levels 1 and 2
Solicitation # HT942526BCRPBTA122
The Department of Defense, through the Defense Health Agency Contracting Activity, is soliciting applications for the Fiscal Year 2026 Breast Cancer Research Program Breakthrough Award Levels 1 and 2 under solicitation number HT942526BCRPBTA122. This mechanism is designed to support high-potential research aimed at achieving breakthroughs in breast cancer, requiring all applications to address at least one overarching FY26 BCRP challenge or provide a strong justification for an exception. The program offers two funding levels with distinct research scopes, including a Population Science Studies option under Level 2 that may allow for increased funding and an extended period of performance. Eligible applicants may apply as a single Principal Investigator or through a partnering arrangement involving an Initiating PI and a Partnering PI. The application process follows a two-step sequence, with pre-applications due by November 4, 2026, and full applications due by November 18, 2026. For those utilizing the Partnering PI Option, both investigators must submit full applications to avoid administrative withdrawal. The program emphasizes a focus on research that can lead to clinical application and major impact, with all submissions governed by specific registration and review criteria managed by the grantor.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

8 days ago

DEADLINE

in 2 months
View Details

Ready to Pursue This Opportunity?

Get AI-powered intelligence on this solicitation and the ones like it

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 650+ contractors already using CLEATUS